`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`LIQUIDIA TECHNOLOGIES, Inc.,
`Petitioner,
`
`v.
`
`UNITED THERAPEUTICS CORPORATION,
`Patent Owner.
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`
`
`
`PATENT OWNER’S UNOPPOSED 3rd MOTION TO FILE
`UNDER SEAL
`
`37 C.F.R. § 42.54
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4889-0612-0982.1
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.54, United Therapeutics Corporation (“Patent
`
`Owner”) hereby submits this 3rd Motion to Seal Exhibits 2096 and 2097.
`
`I. Good Cause Exists for Sealing Certain Confidential Information
`The Office Patent Trial Practice Guide provides that “the rules aim to
`
`strike a balance between the public’s interest in maintaining a complete and
`
`understandable file history and
`
`the parties’
`
`interest
`
`in protecting
`
`truly
`
`sensitive information.” 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012). These
`
`rules “identify confidential information in a manner consistent with Federal
`
`Rule of Civil Procedure 26(c)(1)(G), which provides for protective orders for
`
`trade secret or other confidential research, development, or commercial
`
`information.” Id. (citing 37 C.F.R. § 42.54).
`
`The Board has granted a Motion to Seal certain exhibits in their entireties
`
`for similar reasons in Purdue Pharma L.P. v. Depomed, Inc., IPR2014-00377,
`
`paper no. 62 at 4-6 (PTAB March 17, 2015), where “Patent Owner avers that the
`
`‘highly confidential nature of’ the information contained in those documents
`
`makes it ‘impossible to reasonably redact [them] for public disclosure.’” Id. at 4.
`
`The
`
`transcripts of Exhibits 2096 and 2097 were designated as
`
`“Confidential” and “Highly Confidential” in their entireties by Liquidia
`
`Corporation, Petitioner in this proceeding and defendant in the Delaware
`
`litigation. Accordingly, Patent Owner files these excerpts under seal in this
`
`4889-0612-0982.1
`
`
`
`
`
`
`
`
`
`
`
`proceeding per its obligations under the district court protective order, and per
`
`Petitioner’s lack of objection to Patent Owner doing so. Petitioner is the party
`
`with knowledge as to why good cause exists for the confidentiality designation
`
`and why the “‘highly confidential nature of’ the information contained in those
`
`documents makes it ‘impossible to reasonably redact [them] for public
`
`disclosure.” Purdue Pharma L.P. v. Depomed, Inc., IPR2014-00377, Paper No.
`
`62, at 4 (PTAB March 17, 2015).
`
`II. Certification of Non-Publication
`
`On behalf of Patent Owner, undersigned counsel certifies that, to the best
`
`of their knowledge, the information sought to be sealed by this Motion to Seal
`
`has not been published or otherwise made public. Efforts to maintain the
`
`confidentiality of this information have been undertaken by Patent Owner in
`
`the related proceedings noted above.
`
`III. Certification of Conference with Opposing Party Pursuant to
`37 C.F.R. § 42.54
`
`Patent Owner has conferred with Petitioner about both the PTAB’s Default
`
`Protective Order and motion to seal relating to Patent Owner’s confidential
`
`information, and the Parties have agreed to be bound by the PTAB’s Default
`
`Protective Order. Per Appendix B of the Trial Practice Guide, the Default
`
`Protective Order is not being separately filed.
`
`4889-0612-0982.1
`
`
`
`
`
`IV. Protective Order
`The confidential information will be subject to the Default Protective Order
`
`from the Trial Practice Guide, to which the parties have agreed to be bound in this
`
`proceeding.
`
`V. Conclusion
`For the reasons stated above, Patent Owner respectfully requests that
`
`EX2096 and EX2097 remain under seal.
`
`Date: March 16, 2022
`
`
`
`Respectfully submitted,
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Registration No. 35,264
`Foley & Lardner LLP
`3000 K Street, N.W., Suite 600
`Washington, D.C. 20007
`
`
`Counsel for Patent Owner
`
`4889-0612-0982.1
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing MOTION TO
`SEAL, is being served on March 16, 2022 by filing this document through the PTAB
`E2E System as well as delivering copies via email to the following counsel for the
`Petitioner:
`
`
`zLiquidiaIPR@cooley.com
`ielrifi@cooley.com
`emilch@cooley.com
`dkannappan@cooley.com
`ssukduang@cooley.com
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Registration No. 35,264
` Counsel for Patent Owner
`
`
`4889-0612-0982.1
`
`5
`
`